 |
|
|
| |
Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo
Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Brian J. Kirby,1 Cara Nelson,1 Jacqueline Tarrant,1 Mona Vimal,1 Jorge Escobar,1 Qinghua Song,1 Kelvin Li,2 Marc Hellerstein,2 Bryan J. McColgan,1 C. Stephen Djedjos,1 Robert P. Myers1
1Gilead Sciences, Inc., Foster City, CA; 2University of California, Berkeley
References
1. Lawitz, E, et al. EASL 2017, oral GS-009; 2. Fullerton MD, et al. Nat Med 2013;19:1649-54; 3. Harriman G, et al. PNAS 2016;113:E1796-805; 4. Lambert JE, et al.
Gastroenterology 2014;146:726-35; 5. Bates J, et al. EASL 2017, poster FRI-352; 6. Bates J, et al. AASLD 2017, poster 2053; 7. Wei L, et al.
AASLD 2015, poster PS1938; 8. Stiede K, et al. Hepatology 2017;66:324-34; 9. Hellerstein MK, et al. Am J Physiol 1992;263:E988-1001.
|
| |
|
|
|
|
|
